EP4322860A1 - Aspirat corporel utilisé à des fins diagnostiques - Google Patents

Aspirat corporel utilisé à des fins diagnostiques

Info

Publication number
EP4322860A1
EP4322860A1 EP22722201.5A EP22722201A EP4322860A1 EP 4322860 A1 EP4322860 A1 EP 4322860A1 EP 22722201 A EP22722201 A EP 22722201A EP 4322860 A1 EP4322860 A1 EP 4322860A1
Authority
EP
European Patent Office
Prior art keywords
aspirate
invasive device
treatment
connection
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22722201.5A
Other languages
German (de)
English (en)
Inventor
Anke Görgner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP4322860A1 publication Critical patent/EP4322860A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B10/0064—Devices for taking samples of body liquids for taking sweat or sebum samples
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0096—Casings for storing test samples
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150015—Source of blood
    • A61B5/150022—Source of blood for capillary blood or interstitial fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150053—Details for enhanced collection of blood or interstitial fluid at the sample site, e.g. by applying compression, heat, vibration, ultrasound, suction or vacuum to tissue; for reduction of pain or discomfort; Skin piercing elements, e.g. blades, needles, lancets or canulas, with adjustable piercing speed
    • A61B5/150061—Means for enhancing collection
    • A61B5/150099—Means for enhancing collection by negative pressure, other than vacuum extraction into a syringe by pulling on the piston rod or into pre-evacuated tubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150343—Collection vessels for collecting blood samples from the skin surface, e.g. test tubes, cuvettes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150351—Caps, stoppers or lids for sealing or closing a blood collection vessel or container, e.g. a test-tube or syringe barrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B2010/008—Interstitial fluid

Definitions

  • the subject matter of the present application is a non-invasive device for removing body aspirate, the use of this non-invasive device for providing body aspirate and the use of the correspondingly provided body aspirate for diagnostic purposes.
  • the capillary blood provided in bloody cupping is blood drawn from the capillaries (i.e., capillaries) of the body. It is used in a large number of laboratory tests and especially in rapid diagnostics with test strips to determine blood sugar levels in diabetes mellitus. As "quasi-arterial blood” that has not yet passed through the entire tissue, readings for certain substances such as glucose, amino acids, proteins, etc. can differ from readings for whole blood.
  • the capillary blood provided by bloody cupping is therefore not suitable for determining all the measured values that can be determined in whole blood and in particular not for determining tumor markers.
  • Tumor markers are usually substances in the blood that occur in increased concentrations in tumor diseases. They can come from the body in response to cancer or from Cancer cells themselves are formed. These markers are often suitable for assessing the course but also the success of cancer therapy.
  • tumor markers are usually determined in whole blood, only those values or markers that circulate systemically, i.e. throughout the body, are conspicuous in the analysis. However, the targeted diagnosis of changes in regionally restricted areas of the body cannot be detected or recorded by such whole blood analyses.
  • the object of the present invention was therefore to provide a device which, on the one hand, enables targeted diagnostics of regional body area changes, but at the same time does not suffer from the limitations of methods for providing capillary blood, such as cupping.
  • a non-invasive device (100) for removing body aspirates comprising: a suction chamber (110) with an opening (120) on the treatment side around skin tissue in a Expose existing treatment pressure, and a connection for a negative pressure source (130) for generating the treatment pressure, characterized in that the non-invasive device (100) has at least one further connection for removing body aspirate (140).
  • Device within the meaning of the present invention refers to the "non-invasive device” (100) according to the invention as defined herein.
  • Body aspirate within the meaning of the present invention refers to the endogenous substance that is provided by using the device according to the invention.
  • Body aspirate differs in viscosity and color from capillary blood and can be clearly distinguished from it. While capillary blood can only be taken from parts of the body that are very well supplied with blood, such as fingertips or earlobes, body aspirate can in principle be taken from any part of the body. Furthermore, close the capillary blood collection from the capillary bed during the Remove the blood vessels so quickly that usually only small amounts of up to 0.5 ml of capillary blood can be provided per removal.
  • Body aspirate according to the invention can be provided with volumes of at least 20 ml per removal process or removal point.
  • the non-invasive device (100) according to the invention can be made of any material that is suitable for withstanding the treatment pressure applied.
  • the non-invasive device is formed of plastic, such as polyethylene or acrylic plastic, or glass.
  • the device according to the invention can be designed to be transparent or opaque.
  • transparent material When using transparent material, the user can visually assess how the applied treatment pressure or negative pressure affects the body part or body region.
  • An opaque design can be advantageous in particular for the removal of body aspirates from locations which are visible to the person to be treated. Experience has shown that a not inconsiderable number of people react with circulatory weakness at the sight of blood or the removal of body aspirates.
  • the device according to the invention can be designed to be largely opaque, but it can have a transparent area as a control window for the user.
  • Treatment pressure in the sense of the present application is a negative pressure. Maintaining and/or regulating the treatment pressure, for example, in the range from -0.1 to -1.0 bar and more.
  • a vacuum pump and in particular a medically approved vacuum pump is used as the negative pressure source.
  • This pump preferably has an infinitely variable vacuum generator.
  • a hand pump is used. With a high level of user comfort, a high suction effect of -1 bar and more can be achieved in comparison to other vacuum processes.
  • the device according to the invention preferably has a connection for a vacuum source (130), which is positioned centrally and opposite a base area defined by the opening on the treatment side.
  • connection for the vacuum source (130) is designed as a one-way valve.
  • the necessary valve can be permanently installed in the connection for the vacuum source.
  • a valve is introduced into the connection for the vacuum source before the device according to the invention is used.
  • the connection for the vacuum source (130) is preferably conical, in particular tapering away from the suction chamber.
  • the inner diameter of the connection for the vacuum source (130) located outside the suction chamber is preferably about 5 mm.
  • the side wall S of the suction chamber can be reinforced and/or thickened in the area of the connection for the vacuum source (130).
  • the side wall S may have, in the area of the port (130), an insert for a vacuum valve and/or a guide, the orientation of which is perpendicular to the surface defined by the treatment-side opening (120).
  • the guide is preferably integral with the side wall S and is formed from the same material.
  • the radius of the treatment-side opening (120) can vary, for example, depending on the body site or body region to be treated.
  • the treatment-side opening preferably has an inside diameter (ID) between 50 mm and 90 mm, more preferably between 60 mm and 80 mm, and most preferably between 65 mm and 75 mm. An inner diameter of 72 mm is particularly preferred.
  • the outer diameter (OD) is preferably between 65 and 105 mm, preferably 89 mm.
  • the treatment-side opening (120) has a rounded edge. Such a configuration is less painful for the person being treated when it is used.
  • the opening (120) on the treatment side has a widened border (121).
  • the widened border (121) can also be rounded.
  • the widened edge termination (121) an easier intervention Closing means, such as a rubber seal or a screw cap, for the treatment-side opening (120).
  • the edge termination (121) is preferably designed as a plastic thread (122).
  • the widened edge termination (121) or the plastic thread (122) preferably has a thickness SR of between 6 mm and 8 mm, preferably 7 mm and 8 mm, in particular approx. 7.5 mm.
  • Its length LR is preferably between 11 mm and 14 mm, preferably between 12 mm and 13 mm and in particular approximately 12.7 mm.
  • the side wall S of the suction chamber (110) can have any thickness S that is stable under the applied vacuum.
  • the volume of the suction chamber (110) may vary depending on the body site or body region to be treated.
  • the suction chamber (110) has a volume between 100 cc and 300 cc , more preferably between 150 cc and 250 cc , and most preferably between 200 cc and 230 cc .
  • a volume of about 215 cm 3 is particularly preferred. It is of course possible to use several smaller volume devices instead of one large volume non-invasive device (100) - if the body part to be treated allows it, such as the back.
  • the overall length L (measured vertically from the base area defined by the treatment-side opening to the extreme end of the connection for the vacuum source (130)) of the device is between 60 mm and 90 mm. In a preferred embodiment, the overall length L including the sealing surface (e.g. screw-on cover) is approximately 82 mm.
  • the side wall of the suction chamber is preferably formed with elements for closing the treatment-side opening (120), ie a removable sealing surface.
  • the opening can be closed or sealed, for example, by means of a suitable rubber seal or by means of a cover with a screw cap, for example a screwable cover (150).
  • the twist-lock cap (150) is made of the same material as the formed suction chamber according to the invention. Closing the opening seals body aspirate in the suction chamber preferably in an airtight manner and thus avoids or reduces oxidation processes in the body aspirate.
  • the device according to the invention can thus serve as a body aspirate collection container.
  • the device according to the invention has at least one further connection (140) which is designed for removing body aspirate.
  • the connection for removing the body aspirate (140) preferably has an inner diameter of 4 mm to 5 mm, in particular approx. 4.5 mm.
  • the connection for removing the body aspirate (140) is designed as a Luer system.
  • the further connection for removing the body aspirate (140) to the connection for the negative pressure source (130) on the surface of the device or suction chamber according to the invention is at an angle between 25° and 40°, more preferably between 30° and 35° and most preferably disposed at about 32.5°.
  • Body aspirate can be removed through the connection for body aspirate removal (140) while the device (100) is placed on the body removal site or when the device (100) is closed by the screw cap (150).
  • the device (100) according to the invention enables the removal of body aspirate without the use of additional means or elements such as spreading elements, e.g. skin stretchers, or adhesive rings.
  • a further aspect of the present invention relates to a body aspirate which is provided by using the non-invasive device according to the invention.
  • the body aspirate provided by the method described below is obtained regionally from the body site or body region where the non-invasive device according to the invention is used. This makes it possible to detect local changes in the body before a disease or at least parameters characterizing this disease spread to the entire organism.
  • Locally taken body aspirate can do that have a significantly higher concentration of locally specific analytes to be detected than whole blood or blood taken intravenously.
  • body aspirate that was taken from a body site specific for colon carcinoma e.g. thoracic vertebra Th 10 to Th 12 on the left
  • the body aspirate provided according to the invention thus enables both more sensitive and locally targeted or organ-specific diagnostics in terms of early detection.
  • the diagnostics here can relate to changes in blood components, inflammatory markers (cytokines), cell-free nucleic acids such as DNA and/or RNA fragments and/or tumor markers.
  • cytokines inflammatory markers
  • cell-free nucleic acids such as DNA and/or RNA fragments and/or tumor markers.
  • CTC circulating tumor cells
  • CETC circulating epithelial tumor cells
  • the location of the body parts or body regions for body aspirate removal can be determined, for example, by palpation and/or allocation of the organs to be examined using head zones.
  • the head zone is defined as a part of the body or skin area in which, due to the articulated body structure, there is a cross-connection between the somatic and autonomic nervous system via the associated spinal cord segment.
  • Specific internal organs are assigned to specific parts of the body or skin area.
  • the Head's zone which is associated with a specific organ, can extend over several dermatomes, but has a reflexively significant maximum point.
  • dermatome describes the segmental skin area sensitively innervated by the spinal cord nerves (spinal nerves) or the corresponding part of the body.
  • body aspirate is removed at least at this maximum point.
  • body aspirate is removed from all dermatomes associated with the organ to be examined.
  • the removal that is possible according to the invention via head zones allows a significantly increased flexibility and expanded application possibilities compared to an exclusively local removal, for example in the case of skin infections, among other things, or directly on the organ or tissue.
  • the method for removing body aspirate using the device according to the invention comprises the following steps: a) placing the non-invasive device on the part of the body or body region from which body aspirate is to be removed and applying negative pressure in order to expose skin tissue to a treatment pressure present in the suction chamber or .to suck. Care should be taken to ensure that the non-invasive device (100) is in full contact with the skin tissue or surface to avoid air aspiration.
  • the duration of suction step (a) is preferably between 30 and 90 seconds.
  • b) Deactivating the vacuum means and equalizing the pressure in the suction chamber to remove the non-invasive device.
  • c) Disinfecting the skin tissue or body site or body region previously encompassed by the treatment-side opening of the non-invasive device.
  • d) activating the disinfected skin area.
  • e) Reapplying the non-invasive device to the same part of the body or body region as in step (a) and applying the treatment pressure by means of a vacuum source over a defined period of time. It is again necessary to ensure that the non-invasive The device (100) has full contact with the skin tissue or the skin surface in order to avoid air being sucked in.
  • the duration of the aspiration step (e) is preferably between 3 and 5 minutes. f) Deactivation of the negative pressure source or the vacuum means and pressure equalization of the suction chamber.
  • the removal according to the invention is thus characterized, among other things, by its simple implementation, speed and relative comfort. Furthermore, it is possible to remove relatively large amounts of body aspirate of at least 20 ml and more.
  • Activation of the skin area allows body aspirate to escape when negative pressure is applied and can preferably be done by scratching and/or lancetting.
  • a sterile lancet can be used for this, for example. How often the lancet is pushed vertically through the superficial skin depends on the size of the skin area. If drops of blood appear during activation of the skin area, these should be removed before step (e), for example with the help of a gauze swab.
  • the body aspirate may be removed from the treated skin tissue area through the body aspirate removal port prior to removal of the suction chamber.
  • the non-invasive device containing the removed body aspirate is closed directly after deactivating the negative pressure, equalizing the pressure and removing it from the treated part of the body. The body aspirate can then be removed through the connection (140) at a later point in time.
  • an anticoagulant may be introduced into the suction chamber, e.g. B. by connecting the body aspirate collection.
  • coagulant is located in the receptacle into which the body aspirate from the suction chamber is placed.
  • body aspirate can be removed from the skin tissue area through the treatment-side opening directly from the suction chamber, i. H. not be removed from the body aspirate collection port.
  • Disinfection steps follow the hygiene measures known to those skilled in the art.
  • the area where the body aspirate is taken is then carefully disinfected and can be covered or bandaged with a sterile wound dressing.
  • a further aspect of the present application relates to the use of a body aspirate, which has been made available through the use of the non-invasive device according to the invention, for diagnostic purposes.
  • the body aspirate provided according to the invention enables the determination of all measured values that can also be determined in whole blood, eg liver values, kidney values, etc.
  • the body aspirate can be taken from the corresponding head zone and/or from any other point on the body surface.
  • the body aspirate can be used in particular to determine erythrocytes, leukocytes, thrombocytes, blood lipids, blood salts, blood sugar, proteins, enzymes, metabolic products, inflammatory markers (cytokines), CTCs (circulating tumor cells), hormone coagulation factors, cell-free nucleic acids such as DNA and/or RNA fragments, and/or tumor markers are used.
  • the tumor markers SCC, AFP, CA 15-3, CA 19-9, CA 72-4, CA 125, calcitonin, CEA, hCG, NSE, PSA and/or TG can be determined.
  • the diagnostics according to the invention can be used both in a targeted manner for early detection and for monitoring the course of tumor diseases. The determination of SCC is most preferred.
  • the tumor marker SCC (Squamous cell carinoma antigen) is an immunological parameter that indicates the existence of a squamous cell carcinoma in the body. Squamous epithelium is widespread, it is found on the organs of the gastrointestinal tract, the respiratory tract, on those of the urogenital tract and on the skin. If the SCC in venous blood (IV) is increased, there is a suspicion of squamous cell carcinoma.
  • SCC IV is not organ specific, such as the prostate specific antigen PSA for prostate. If the SCC i.v. is elevated, the location of the primary tumor or the location of the metastases can be anywhere where there is squamous epithelium (squamous cell). Therefore, the SCC i.v. as a non-specific value and is currently only used for follow-up, and
  • SCC i.v. increases the probability of the existence of a higher stage 3 or 4 tumor more than 80%.
  • the SCC is i.v. increased only under 3%.
  • SCC is determined in the body aspirate provided according to the invention, this is different: 1) an exact localization of the primary tumor or the metastases can be made by SCC in the body aspirate. Respiratory organs can be specifically examined in the upper dermatomes C3 to TH5, digestive organs in the middle dermatomes T6 to L1 and urogenital organs in the lower lumbosacral dermatomes L2 to S4, and
  • SCC in body aspirate is suitable for the first time as an early test for tumors in stages 0-2.
  • SCC can be increased in colon cancer, cervical cancer, anal cancer, penile cancer, esophageal cancer, certain forms of lung cancer and/or tumors in the ear, nose and throat area.
  • Alpha-fetoprotein is a tumor marker that can be elevated in ovarian and testicular germ cell tumors and liver tumors, among other things.
  • the CA 15-3 marker can be indicative of cirrhosis of the liver, inflammation of the body or breast cancer.
  • CA 19-9 is a marker for tumors of the rectum, colon, stomach, liver, bile ducts or pancreas.
  • the cancer antigen CA 125 can be indicative of tumors of the ovaries, ovarian carcinoma. Elevated levels of the protein calcitonin and/or TG (thyroglobulin) can be an indication of thyroid tumors.
  • Neuron-specific enolase (NSE) can be indicative of certain forms of lung cancer.
  • Elevated levels of prostate-specific antigen can indicate prostate cancer.
  • the carcinoembryonic antigen (CEA) can be determined, among other things, if there is a suspicion of tumors in the stomach, lungs, female breast, stomach, pancreas, thyroid, colon or rectum.
  • the marker is also specific for liver cirrhosis and inflammation.
  • Human chorionic gonadotropin (hCG) can be used as an indication for tumors of the germ cells of the ovaries and testicles.
  • the CA 72-4 marker can indicate ovarian cancer or an inflamed pancreas. The marker specificities mentioned are examples and should not be understood as exhaustive.
  • body aspirate is used to determine the SCC value, or if several blood values and/or tumor markers are determined, at least to determine the SCC value.
  • Body aspirate according to the invention can be used in particular for diagnosing the condition or diseases of the thyroid, lungs, esophagus, bile ducts, liver, pancreas, urinary bladder, prostate, testicles, stomach, female breast, duodenum, small intestine , colon/rectum, ovary, cervix, uterus, kidney, skin and/or brain.
  • FIG. 1 Non-invasive device (100) comprising a suction chamber (100), a connection for a vacuum source (130), a connection for removing body aspirate (140) and a screwable cover
  • FIG. 2 Top view of the non-invasive device (100).
  • FIG. 3 Cross-sectional drawing of the non-invasive device (100) with a screwable cover (150) (3A) and without a screwable cover (3B). Specifications are in mm.
  • Figure 3C shows a detail of the plastic thread (122).
  • Figure 4 Figure 4 shows patients with tumors on the squamous epithelium of various
  • Blood was taken intravenously (blood iv) and body aspirate within the meaning of the present invention from a 63-year-old patient with colon carcinoma.
  • CEA and Ca 19-9 are normal for both IV blood and body aspirate, a significantly higher value (factor greater than 100) for SCC can be detected in body aspirate, which is indicative of colon carcinoma. A corresponding detection is not possible with blood IV; here the SCC value remains below the usual limit of 1.5 ng/ml. 2. Ovarian carcinoma
  • Blood was taken intravenously (blood iV) and body aspirate within the meaning of the present invention from a 51-year-old patient with ovarian carcinoma.
  • Blood was taken intravenously (blood iv) and body aspirate within the meaning of the present invention from a 59-year-old patient with prostate carcinoma. All of the determined marker values in body aspirate show a significantly higher exceeding of the normal range and provide an indication of prostate carcinoma. 4. Rectal carcinoma
  • Blood was taken intravenously (blood IV) and body aspirate within the meaning of the present invention from a 54-year-old and a 43-year-old patient with rectal carcinoma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • External Artificial Organs (AREA)

Abstract

La présente invention concerne un dispositif non invasif pour retirer un aspirat corporel, l'utilisation dudit dispositif non invasif pour rendre l'aspirat corporel disponible, et l'utilisation de l'aspirat corporel disponible à des fins diagnostiques.
EP22722201.5A 2021-04-14 2022-04-11 Aspirat corporel utilisé à des fins diagnostiques Pending EP4322860A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21168365.1A EP4074263A1 (fr) 2021-04-14 2021-04-14 Aspiration de corps vitreux destiné à l'utilisation dans le diagnostic
PCT/EP2022/059588 WO2022218902A1 (fr) 2021-04-14 2022-04-11 Aspirat corporel utilisé à des fins diagnostiques

Publications (1)

Publication Number Publication Date
EP4322860A1 true EP4322860A1 (fr) 2024-02-21

Family

ID=75529871

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21168365.1A Withdrawn EP4074263A1 (fr) 2021-04-14 2021-04-14 Aspiration de corps vitreux destiné à l'utilisation dans le diagnostic
EP22722201.5A Pending EP4322860A1 (fr) 2021-04-14 2022-04-11 Aspirat corporel utilisé à des fins diagnostiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP21168365.1A Withdrawn EP4074263A1 (fr) 2021-04-14 2021-04-14 Aspiration de corps vitreux destiné à l'utilisation dans le diagnostic

Country Status (2)

Country Link
EP (2) EP4074263A1 (fr)
WO (1) WO2022218902A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10219924A1 (de) * 2002-01-24 2003-07-31 Pierre Foss Vakuumentnahme II
US7335166B2 (en) * 2002-05-22 2008-02-26 Spectrx, Inc. System and method for the extraction and monitoring of a biological fluid
CA2655017A1 (fr) * 2009-02-20 2010-08-20 Abdeltif Essalik Detection biomedicale non effractive et systemes de surveillance
CN112638252B (zh) * 2018-09-05 2024-05-03 光云大学校产学协力团 血糖测量仪和使用该血糖测量仪的血糖测量系统
CN112386289A (zh) * 2020-11-19 2021-02-23 中国科学院空天信息创新研究院 汗液促排装置、汗液收集系统及汗液收集方法

Also Published As

Publication number Publication date
WO2022218902A1 (fr) 2022-10-20
EP4074263A1 (fr) 2022-10-19

Similar Documents

Publication Publication Date Title
DE69909830T2 (de) Vorrichtung zur halterung für mindestens eine medizinische drain
DE69728525T2 (de) Mittels vakuum verbesserter transdermaler flüssigkeitstransport
DE3806008C2 (de) Kapillarfiltrations- und Sammelvorrichtung zur Überwachung eines physiologischen Bestandteils des Blutes
DE60211142T2 (de) Probenentnahmevorrichtung und verfahren zur entnahme von proben von körpersubstanzen sowie verfahren zur herstellung einer probenentnahmevorrichtung
DE60209488T2 (de) Detektion einer verlagerung der nadel
DE69829399T2 (de) Katheter mit neben dem distalen ende angeordnetem druckgeber
EP1404217B1 (fr) Mesurage de la concentration de substances dans des organismes vivants par microdialyse
DE2611721B2 (de) Vakuum-Sauggerät zum Absaugen von Gewebeserum
CN107260226B (zh) 一种循环肿瘤细胞的体内富集装置
DE2235337B2 (de) Sauggerät für die Entnahme von Zellenproben
DE112011103054T5 (de) Verfahren zur Bewertung der Schluckmotorikfunktion
EP0742724A1 (fr) Moyen de marquage visuel de tissus corporels
AT514209B1 (de) Vorrichtung zur Probennahme
DE60117470T2 (de) Gerät zur auslösung einer immunantwort in der krebstherapie
EP4322860A1 (fr) Aspirat corporel utilisé à des fins diagnostiques
Trivedi et al. Salivary sialic acid as marker of oral cancer
DE19963034A1 (de) System zur verbesserten Bestimmung des Glukosespiegels anhand von Messungen in interstitieller Flüssigkeit
Cho et al. Case report: Unilateral papilledema in a dog with a large suprasellar mass and suspected intracranial hypertension: insights from funduscopy, optical coherence tomography, and magnetic resonance imaging
CN217219861U (zh) 一种治疗脊髓损伤或感染的硬膜内冲洗引流管
AT501013B1 (de) Vorrichtung und verfahren zur messung der indikatorkonzentration und apparateclearance bei extrakorporalen blutbehandlungsverfahren
de Freitas et al. Surgical excision combined with electrochemotherapy in the treatment of squamous cell carcinoma in a feline: Case report
EP3849625A1 (fr) Système pour analyser des fluides d'origine corporelle ou des fluides en contact avec le corps
DE102018005024B4 (de) Verfahren zur Erfassung von Indikatoren
Avetikov et al. Features of ultrasound diagnostics of postoperative hypertrophic and keloid scars
DE10219924A1 (de) Vakuumentnahme II

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250612